StoneX Maintains Hold Rating on Palantir Technologies Inc.
Analyst Yi Fu Lee of StoneX has maintained a hold rating on Palantir Technologies Inc. shares.
Stocks · News reference
Palantir Set to Receive NHS Contract Extension
Palantir Technologies is reportedly in line for an extension of its contract with the UK's National Health Service.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Prediction: $5,000 Invested in Palantir Will Be Worth This Much by 2031
Despite Palantir's impressive 92% year-over-year revenue growth and real productivity gains for clients, analyst Will Healy predicts a $5,000 investment today will be worth approximately the same by 2031. The stock's elevated 55 price-to-sales ratio has already priced in future growth, and as revenue growth decelerates from current levels to an estimated 31% annually, valuation compression will likely pressure the stock price over the next five years.
The Biggest Stock Winners and Losers From the Midterm Elections
Following the midterm elections, certain stocks are positioned to benefit or suffer based on potential policy shifts. Retailers like Amazon, Shopify, and e.l.f. Beauty could gain from tariff rollbacks, while neoclouds like Space Exploration Technologies and other data center companies face headwinds from tougher permitting. Palantir Technologies may see slower government growth depending on administrative changes.
Reported Earlier: AmeriLife And Palantir Announce Enterprise Partnership To Bring AI-Driven Transformation To Insurance And Retirement Distribution
'UK plans to extend Palantir’s NHS contract as it draws up plans for potential replacement' - Financial Times
Why Is Palantir Stock Falling, and is it a Buying Opportunity?
Palantir Technologies stock declined following the company's Q3 earnings report that disappointed investors. Despite some positive developments, valuation concerns remain a focus for the market, raising questions about whether the dip presents a buying opportunity.